Bruker Corporation Common Stock (BRKR)

FairStock Score: 46/100 — MIXED

Key Financials

Strengths

• Generates $212 million in annual free cash flow (3.9% yield on market cap)
• Established organization with 11,085 employees providing operational scale

Concerns

• Revenue declining at 0.2% year-over-year signals potential demand weakness or market share loss

AI Analysis

Bruker Corporation Common Stock is a small-cap healthcare company valued at $5.5 billion. The business generates $3.5 billion in annual revenue with a 0.4% net margin and $212 million in free cash flow. From a quality standpoint, Bruker shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 1.8 in the grey zone. On valuation, the stock is 3.2% FCF yield. Growth dynamics show revenue growing at -0.2% and profit growth of 89.8%. Our composite FairStock Score of 46/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $212 million in annual free cash flow (3.9% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer